{"id":598218,"date":"2022-05-02T18:04:01","date_gmt":"2022-05-02T18:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=598218"},"modified":"2022-05-02T18:04:01","modified_gmt":"2022-05-02T18:04:01","slug":"leukapheresis-market-worth-91-million-by-2026-growth-trends-size-share-industry-demand-global-analysis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/leukapheresis-market-worth-91-million-by-2026-growth-trends-size-share-industry-demand-global-analysis_598218.html","title":{"rendered":"Leukapheresis Market worth $91 million by 2026 – Growth, Trends, Size, Share, Industry Demand, Global Analysis"},"content":{"rendered":"
\n
\"Leukapheresis<\/a><\/div>\n
\n
Key players in the leukapheresis products and leukopaks market: Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy)<\/div>\n<\/div>\n<\/div>\n
Leukapheresis Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size.<\/div>\n

According to the new market research report “<\/strong>Leukapheresis Market<\/a> by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) – Global Forecast to 2026″,<\/strong> published by MarketsandMarkets™, the global Leukapheresis Market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%.<\/p>\n

Download PDF Brochure: <\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=20283148<\/a><\/p>\n

The Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis andc cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.<\/p>\n

By type, the leukapheresis disposables segment is expected to account for the largest share of the leukapheresis products market<\/strong><\/p>\n

Based on type, the leukapheresis market is segmented into leukapheresis disposables and leukaphersis devices. The large share of the leukapheresis disposables segment can be attributed to the recurrent use of disposables during leukapheresis procedures, increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.<\/p>\n

On the basis of application, research applications segment expected to grow at highest CAGR in the leukapheresis products market in the forecast period<\/strong><\/p>\n

Based on application, the leukapheresis market is segmented into research and therapeutic applications. The research applications segment is expected to grow at the highest CAGR in the leukapheresis products market during the forecast period.  The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies and leukapheresis-derived primary cells in drug development.<\/p>\n

On the basis of end user, blood component providers & blood centers segment holds the highest market share in the leukapheresis products market<\/strong><\/p>\n

Based on end user, the leukapheresis market is segmented into blood component providers & blood centers, academic and research institutes, pharmaceutical & biotechnology companies, hospitals & transfusion centers. Blood component providers & blood centers hold the largest share in this market. The large share of this segment can be attributed to growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=20283148<\/a><\/p>\n

On the basis of type, in the leukopaks market, the diseased leukopaks segment is projected to grow at the highest rate forecast period<\/strong><\/p>\n

Based on type, the market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs.  In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.<\/p>\n

On the basis of indication, the acute lymphocytic leukemia segment holds the largest share in the leukopaks market<\/strong><\/p>\n

Based on indication, the acute lymphocytic leukemia segment accounts for the largest share of the market, by indication. The large share of this segment can be attributed to the increasing focus of pharmaceutical companies on the development of leukopak-based cell therapies for the treatment of acute lymphocytic leukemia (ALL) and a high number of CAR T-cell therapy clinical trials for ALL.<\/p>\n

On the basis of end user, the pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR in the leukopaks market in the forecast period<\/strong><\/p>\n

Based on  end user, the leukopaks market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Pharmaceutical and biotechnology companies are projected to grow at the highest CAGR in this market in the forecast period. Thi highest growth rate can be attributed to increasing collaboration of pharmaceutical companies with academic institutes, research centers, and hospitals for new drug development.<\/p>\n

Speak to Analyst: <\/strong>https:\/\/www.marketsandmarkets.com\/speaktoanalystNew.asp?id=20283148<\/a><\/p>\n

North America to dominate the Leukapheresis products and leukopaks market during the forecast period<\/strong><\/p>\n

The leukapheresis market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The large share of this region can be attributed to the increasing adoption of leukapheresis products for the development of leukoreduced plasma and leukoreduced RBCs, growing adoption of leukopaks as a source of primary cells for research applications, increasing number of clinical trials for the development of CAR T-cell therapy using leukopaks.<\/p>\n

Prominent players in the Leukapheresis products and leukopaks market include Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Charles River Laboratories (US), AllCells, LLC (US),  and StemExpress, LLC. (US).<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/leukapheresis-market-20283148.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Key players in the leukapheresis products and leukopaks market: Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-598218","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/598218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=598218"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/598218\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=598218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=598218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=598218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}